A spin-out from Oxford University, Oxford BioSignals Ltd was formed in 2000 in order to develop a range of monitoring algorithms across a variety of applications.

In 2009, the industrial arm of the business that arose from the broader implementation of the technology was sold to Rolls Royce. The company then focussed on the healthcare applications of the Visensia®technology and in the same year became OBS Medical.